Bioventus (NYSE:BVS – Get Rating) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “Bioventus Inc. delivers clinically proven, cost-effective products which help people heal quickly and safely. It includes offerings for osteoarthritis, […]